Spectrum and Impact of Reported Side Effects of Omalizumab in Patients With Chronic Urticaria: A Long-Term Multicenter Real-World Study

    May 2025 in “ Clinical & Experimental Allergy ”
    Reineke Soegiharto, Esther Van der Wind, Mehran Alizadeh Aghdam, Jennifer Astrup Sørensen, Esmee van Lindonk, Fatih Demir, Nasser Mohammad Porras, Yoshimi Matsuo, Lea Kiefer, André C. Knulst, Marcus Maurer, Carla Ritchie, Michael Rudenko, Emek Kocatürk, Roberta Fachini Jardim Criado, Stamatios Gregoriou, Tatjana Bobylev, Andreas Kleinheinz, Shunsuke Takahagi, Michihiro Hide, Ana M. Giménez‐Arnau, Andaç Salman, Rabia Öztaş Kara, Bahar Sevimli Dikicier, Martijn B. A. van Doorn, Simon Francis Thomsen, J. M. P. A. van den Reek, Heike Röckmann
    TLDR Omalizumab is generally safe for chronic urticaria, but hair loss is a common side effect.
    The study confirmed the safety and tolerability of omalizumab in patients with chronic urticaria, but highlighted a wide variation in reported side effects across different centers, suggesting that awareness influences reporting. Hair loss was noted as a more prevalent side effect than previously described, indicating a need for further attention. Side effects were more frequently reported in patients with characteristics suggesting reduced effectiveness of omalizumab, possibly due to a negative association with the drug and an increased disease burden. The availability of new therapies may influence treatment decisions, affecting not only omalizumab-refractory patients but also those who respond well to the treatment.
    Discuss this study in the Community →

    Research cited in this study

    2 / 2 results